142 related articles for article (PubMed ID: 8596040)
1. Human natural yeast killer toxin-like candidacidal antibodies.
Polonelli L; De Bernadis F; Conti S; Boccanera M; Magliani W; Gerloni M; Cantelli C; Cassone A
J Immunol; 1996 Mar; 156(5):1880-5. PubMed ID: 8596040
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.
Polonelli L; De Bernardis F; Conti S; Boccanera M; Gerloni M; Morace G; Magliani W; Chezzi C; Cassone A
J Immunol; 1994 Mar; 152(6):3175-82. PubMed ID: 8144911
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity.
Magliani W; Conti S; de Bernardis F; Gerloni M; Bertolotti D; Mozzoni P; Cassone A; Polonelli L
Nat Biotechnol; 1997 Feb; 15(2):155-8. PubMed ID: 9035141
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes.
Magliani W; Conti S; Salati A; Vaccari S; Ravanetti L; Maffei DL; Polonelli L
FEMS Yeast Res; 2004 Oct; 5(1):11-8. PubMed ID: 15381118
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii.
Séguy N; Cailliez JC; Delcourt P; Conti S; Camus D; Dei-Cas E; Polonelli L
Mol Med; 1997 Aug; 3(8):544-52. PubMed ID: 9307982
[TBL] [Abstract][Full Text] [Related]
6. Killer anti-idiotypes in the control of fungal infections.
Magliani W; Conti S; Arseni S; Frazzi R; Salati A; Polonelli L
Curr Opin Investig Drugs; 2001 Apr; 2(4):477-9. PubMed ID: 11566002
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies.
Polonelli L; Séguy N; Conti S; Gerloni M; Bertolotti D; Cantelli C; Magliani W; Cailliez JC
Clin Diagn Lab Immunol; 1997 Mar; 4(2):142-6. PubMed ID: 9067647
[TBL] [Abstract][Full Text] [Related]
8. Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade.
Polonelli L; Beninati C; Teti G; Felici F; Ciociola T; Giovati L; Sperindè M; Lo Passo C; Pernice I; Domina M; Arigò M; Papasergi S; Mancuso G; Conti S; Magliani W
PLoS One; 2014; 9(8):e105727. PubMed ID: 25162681
[TBL] [Abstract][Full Text] [Related]
9. Production of anti-toxin antibodies by immunization with Pichia killer toxin-like antiidiotypic monoclonal antibodies.
Snyder C; Seguy N; Lafitte S; Guyard C; Polonelli L; Cailliez JC; Grzych JM
J Eukaryot Microbiol; 1999; 46(5):138S. PubMed ID: 10519290
[No Abstract] [Full Text] [Related]
10. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies.
Conti S; Fanti F; Magliani W; Gerloni M; Bertolotti D; Salati A; Cassone A; Polonelli L
J Infect Dis; 1998 Mar; 177(3):807-11. PubMed ID: 9498471
[TBL] [Abstract][Full Text] [Related]
11. Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis.
Séguy N; Polonelli L; Dei-Cas E; Cailliez JC
FEMS Immunol Med Microbiol; 1998 Sep; 22(1-2):145-9. PubMed ID: 9792073
[TBL] [Abstract][Full Text] [Related]
12. Human, monoclonal and recombinant candidacidal, pneumocysticidal and mycobactericidal antibodies.
Polonelli L
Indian J Chest Dis Allied Sci; 2000; 42(4):259-63. PubMed ID: 15597672
[TBL] [Abstract][Full Text] [Related]
13. From yeast killer toxins to antibiobodies and beyond.
Magliani W; Conti S; Travassos LR; Polonelli L
FEMS Microbiol Lett; 2008 Nov; 288(1):1-8. PubMed ID: 18785931
[TBL] [Abstract][Full Text] [Related]
14. From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.
Polonelli L; Magliani W; Ciociola T; Giovati L; Conti S
Antonie Van Leeuwenhoek; 2011 Jan; 99(1):35-41. PubMed ID: 20714805
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.
Manfredi M; McCullough MJ; Conti S; Polonelli L; Vescovi P; Al-Karaawi ZM; Porter SR
Oral Microbiol Immunol; 2005 Aug; 20(4):226-32. PubMed ID: 15943767
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.
Polonelli L; Magliani W; Conti S; Bracci L; Lozzi L; Neri P; Adriani D; De Bernardis F; Cassone A
Infect Immun; 2003 Nov; 71(11):6205-12. PubMed ID: 14573638
[TBL] [Abstract][Full Text] [Related]
17. In vitro decrease of rat-derived Pneumocystis carinii attachment induced by human natural yeast killer toxin-like antiidiotypic candidacidal antibodies.
Séguy N; Polonelli L; Conti S; Dei-Cas E; Camus D; Cailliez JC
J Eukaryot Microbiol; 1996; 43(5):27S. PubMed ID: 8822831
[No Abstract] [Full Text] [Related]
18. Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes.
De Bernardis F; Santoni G; Boccanera M; Lucciarini R; Arancia S; Sandini S; Amantini C; Cassone A
FEMS Yeast Res; 2010 Jun; 10(4):432-40. PubMed ID: 20402794
[TBL] [Abstract][Full Text] [Related]
19. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine.
Sandini S; La Valle R; Deaglio S; Malavasi F; Cassone A; De Bernardis F
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):215-24. PubMed ID: 21535228
[TBL] [Abstract][Full Text] [Related]
20. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats.
De Bernardis F; Boccanera M; Adriani D; Spreghini E; Santoni G; Cassone A
Infect Immun; 1997 Aug; 65(8):3399-405. PubMed ID: 9234804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
